Vanda Pharmaceuticals (VNDA) 8-K Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

Exhibit 99.1

Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

• Q1 2020 Total net product sales of $58.0 million, a 22% increase year over year

• Advancing the Commercial and Development Pipeline; Initiating Studies forCOVID-19

WASHINGTON – May 6, 2020 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020.

“Our strong financial performance in the first quarter well positions Vanda to continue to innovate and serve our patients, even during this deadly pandemic,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO.

Key Financial and Corporate Highlights

• Total revenues from HETLIOZ^® and Fanapt^® were $58.0 million in the first quarter of 2020, a 22% increase compared to $47.7 million in the first quarter of 2019.

• HETLIOZ^® net product sales were $35.3 million in the first quarter of 2020, a 22% increase compared to $29.0 million in the first quarter of 2019.

• Fanapt^® net product sales were $22.7 million in the first quarter of 2020, a 21% increase compared to $18.8 million in the first quarter of 2019.

• Cash, cash equivalents and marketable securities (Cash) were $312.3 million as of March 31, 2020, representing an increase to Cash of $44.5 million compared to March 31, 2019.

• Net income was $0.5 million for the first quarter of 2020, compared to a net loss of $0.6 million for the first quarter of 2019.

Key Product and Pipeline Highlights

Vanda is working proactively across its business and research units to protect employees and customers, and to maintain business continuity as a result of theCOVID-19 pandemic.

Products

Vanda is encouraged by the strong performance of its commercial products during the first quarter of 2020, driving 22% year-over-year growth. Vanda is implementing marketing and sales strategies aimed at overcoming the disruptions caused by the pandemic. Vanda remains committed to continue innovating and bringing value to patients and prescribers, while advancing and strengthening the awareness and use of its products.

Pipeline

TheCOVID-19 pandemic has impacted clinical research globally, including Vanda’s previously reported clinical trials. New recruitment for the tradipitant atopic dermatitis, gastroparesis and motion sickness programs, as well as the HETLIOZ^® delayed sleep phase disorder study and Fanapt^® bipolar disorder and long acting injectable studies, is currently on hold.

Tradipitant

• The ongoing atopic dermatitis and gastroparesis studies have been adapted in accordance with U.S. Food and Drug Administration (FDA) guidance to protect the health and safety of currently enrolled patients and healthcare providers.

• The results of the recent atopic dermatitis (EPIONE), gastroparesis (VLY686-2301) and motion sickness (Motion Sifnos) studies have all been submitted to peer-review publications.

• See below for details on Vanda’s clinical study, ODYSSEYVLY-686-3501, for the treatment of patients withCOVID-19 Acute Respiratory Distress Syndrome (ARDS).

HETLIOZ^® (tasimelteon)

• Discussions with the FDA are ongoing regarding the supplemental New Drug Applications for HETLIOZ^® in the treatments of jet lag disorder and Smith-Magenis Syndrome.

COVID-19 Therapeutic Program

Vanda initiated the following activities aimed at combatingCOVID-19:

• Vanda announced the initiation of ODYSSEYVLY-686-3501, a Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant for the treatment of patients withCOVID-19 ARDS. Results of this study are expected in the third quarter of 2020.

• Vanda also announced the initiation of the CALYPSO genetics study to evaluate the role of human and viral genetic variations inCOVID-19 infection and disease severity.

• Vanda and the University of Illinois at Chicago (UIC) announced a research partnership to identify small molecule inhibitors of cathepsin-L, a host enzyme required for viral processing.

GAAP Financial Results

Net income was $0.5 million for the first quarter of 2020, compared to a net loss of $0.6 million for the first quarter of 2019. Diluted net income per share was $0.01 in the first quarter of 2020, compared to a diluted net loss per share of $0.01 in the first quarter of 2019.

2020 Financial Guidance

Vanda will continue to assess the impact of the rapidly evolvingCOVID-19 pandemic on its business and operations and will provide future updates to its financial guidance as necessary. The financial guidance communicated by Vanda as of February 25, 2020 is shown below.

Full Year 2020 Financial Objectives	Full Year 2020 Guidance
Total revenues	$240 to $260 million
HETLIOZ® net product sales	$155 to $165 million
Fanapt®net product sales	$85 to $95 million
Year-end 2020 Cash	Greater than $320 million

Conference Call

Vanda has scheduled a conference call for today, Wednesday, May 6, 2020, at 4:30 PM ET. During the call, Vanda’s management will discuss the first quarter 2020 financial results and other corporate activities. Investors can call1-866-688-9426 (domestic) or1-409-216-0816 (international) and use passcode 2583625. A replay of the call will be available on Wednesday, May 6, 2020, beginning at 7:30 PM ET and will be accessible until Wednesday, May 13, 2020 at 7:30 PM ET. The replaycall-in number is1-855-859-2056 for domestic callers and1-404-537-3406 for international callers. The passcode number is 2583625.

The conference call will be broadcast simultaneously on Vanda’s website,www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visitwww.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Various statements in this release, including, but not limited to, the guidance provided under “2020 Financial Guidance” above and statements regarding Vanda’s ODYSSEY study, its collaboration with the UIC and its clinical development programs for tradipitant, HETLIOZ^® and Fanapt^®, are “forward-looking statements” under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s assumptions regarding its ability to continue to grow its business in the U.S.; Vanda’s ability to maintain business continuity during the globalCOVID-19 pandemic and related market volatility; the duration and severity of the globalCOVID-19 pandemic, including prevailing economic conditions and general uncertainties relating thereto that may be unknown and unforeseeable; the ability of Vanda and the UIC to identify small molecule inhibitors of

cathepsin-L; Vanda’s ability to enroll patients in and complete its ODYSSEY study; a failure of tradipitant to be demonstrably safe and effective in the treatment ofCOVID-19 ARDS; Vanda’s ability to complete the clinical development and obtain regulatory approval for tradipitant in the treatment ofCOVID-19 ARDS, atopic dermatitis, gastroparesis and motion sickness; Vanda’s ability to successfully resume the clinical programs that are currently on hold; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s annual report on Form10-K for the fiscal year ended December 31, 2019, which is on file with the SEC and available on the SEC’s website atwww.sec.gov. Additional factors may be described in those sections of Vanda’s quarterly report on Form10-Q for the quarter ended March 31, 2020, to be filed with the SEC in the second quarter of 2020. In addition to the risks described above and in Vanda’s annual report on Form10-K and quarterly reports on Form10-Q, other unknown or unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for share and per share amounts)

(unaudited)

	Three Months Ended
	March 31			March 31
	2020			2019
Revenues:
HETLIOZ®product sales, net	$	35,336		$	28,957
Fanapt®product sales, net		22,664			18,756
Total revenues		58,000			47,713
Operating expenses:
Cost of goods sold excluding amortization		5,207			5,113
Research and development		15,527			13,278
Selling, general and administrative		37,021			31,029
Intangible asset amortization		370			380
Total operating expenses		58,125			49,800
Loss from operations		(125	)		(2,087	)
Other income		1,366			1,485
Income (loss) before income taxes		1,241			(602	)
Provision for income taxes		755			10
Net income (loss)	$	486		$	(612	)
Net income (loss) per share, basic	$	0.01		$	(0.01	)
Net income (loss) per share, diluted	$	0.01		$	(0.01	)
Weighted average shares outstanding, basic		53,806,317			52,752,774
Weighted average shares outstanding, diluted		54,870,146			52,752,774

VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

	March 31			December 31
	2020			2019
ASSETS
Current assets:
Cash and cash equivalents	$	64,950		$	45,072
Marketable securities		247,376			267,057
Accounts receivable, net		29,272			26,367
Inventory		1,320			1,140
Prepaid expenses and other current assets		17,828			14,500
Total current assets		360,746			354,136
Property and equipment, net		3,877			3,864
Operating leaseright-of-use assets		10,875			11,180
Intangible assets, net		22,667			23,037
Deferred tax assets		86,641			87,680
Non-current inventory and other		3,719			3,851
Total assets	$	488,525		$	483,748
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	26,045		$	27,590
Product revenue allowances		33,177			31,915
Total current liabilities		59,222			59,505
Operating leasenon-current liabilities		12,139			12,455
Othernon-current liabilities		778			843
Total liabilities		72,139			72,803
Stockholders’ equity:
Common stock		54			54
Additionalpaid-in capital		635,730			631,307
Accumulated other comprehensive income		781			249
Accumulated deficit		(220,179	)		(220,665	)
Total stockholders’ equity		416,386			410,945
Total liabilities and stockholders’ equity	$	488,525		$	483,748

Corporate Contact:

AJ Jones II

Chief Corporate Affairs and Communications Officer

Vanda Pharmaceuticals Inc.

202-734-3400

pr@vandapharma.com

Elizabeth Van Every

Head of Corporate Affairs

Vanda Pharmaceuticals Inc.

202-734-3400

pr@vandapharma.com

SOURCE Vanda Pharmaceuticals Inc.